NovaBay Pharma (NBY) Misses Q3 EPS by 7c, Miss on Revenues; Lowers FY17 Revenue Outlook Below Consensus

NovaBay Pharma (NYSE: NBY) reported Q3 EPS of ($0.16), $0.07 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $4.09 million versus the consensus estimate of $4.77 million.

2017 Financial Outlook

• NovaBay is revising guidance for 2017 net sales to be between $17.5 million and $18.5 million, a 47% to 55% increase over 2016. This compares with previous guidance for 2017 net sales to be $19 million.
• The Company is affirming its guidance for 2017 gross profit margin on Avenova sales to be in the high 80% range.

GUIDANCE:

NovaBay Pharma sees FY2017 revenue of $17.5-18.5 million, versus the consensus of $18.63 million.

For earnings history and earnings-related data on NovaBay Pharma (NBY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Reading (RDI) Tops Q2 EPS by 4c